<qa>  What is the primary purpose of this study?The primary purpose of this study is to see if giving lower doses of chemotherapy moderately ablative will result in successful bone marrow replacement without as severe side-effects but with permanent control of the disease. Patients will receive a chemotherapy regimen with busulfan, fludarabine, and alemtuzumab followed by an infusion of stem cells, either from a family-related or cord-blood matched donor. 